So with the most recent dilutionary raise they have two quarters worth of funding. They didn't mention anything about Vitrolife, which was meant to be their biggest opportunity transitioning to commercialisation and revenue generation. I can see why the released this after market. I believe China still requires an approval process for the Felix device so transitioning to commercial sales this year or possibly even next year is highly unlikely. Accelerating into the Japanese market was meant to be the saving grace. The half yearly report mentioned they intend on raising 3mil in May which is ~30% of the current market cap. They need to sign agreements hard and fast to turn this around.
MEM Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)